Approved by the FDA for the treatment of wet AMD in 2022, faricimab (brand name Vabysmo) is a newer anti-VEGF drug that utilizes a secondary Fab region to also bind to Angiopoitein-2 (Ang-2) [53]. This evidence concerns the gene ANGPT2 and wet macular degeneration.